{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/11156"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/11156","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"INVESTIGATING MECHANISMS OF CANCER VACCINE-INDUCED TUMOR IMMUNITY AND AUTOIMMUNITY","abstract":"<p><strong>INTRODUCTION: </strong>Pre-clinical and clinical data strongly support the feasibility of employing immunotherapy as a strategy to treat cancer.</p> <p><strong>METHODS: </strong>Using the B16F10 murine melanoma model, we have been investigating mechanisms of T cell-mediated antitumor immunity following immunization with dopachrome tautomerase (DCT), a melanoma-associated antigen.</p> <p><strong>RESULTS: </strong>In <strong>Chapter 2</strong>, we uncovered an interesting dichotomy whereby DCT-specific CD4<sup>+</sup> T cell-mediated tumor protection and autoimmunity are dependent on IL-4/STAT-6 and IFN-g/STAT-4, respectively. Our data also revealed that this phenomenon is extrinsic of CD4<sup>+</sup> T cell polarization.</p> <p>To gain further insight into the targets recognized by CD4<sup>+</sup> T cells, we conducted in <strong>Chapter 3</strong> extensive CD4<sup>+</sup> T cell epitope mapping experiments using overlapping peptide libraries. Interestingly, while we were able to identify “helper” epitopes within DCT that were required for maximal CD8<sup>+</sup> T cell expansion, we were unable to identify “effector” epitopes responsible for tumor rejection. Further examination of the requirements for the generation of CD4<sup>+</sup> T cell effector epitopes showed that post-translational modifications of the protein were involved.</p> <p>In <strong>Chapter 4</strong>, we investigated the modest efficacy afforded by DCT immunization in the context of established B16F10 melanomas. Using intratumoral transcriptional analysis, we demonstrated that the vaccine rapidly promoted an IFN-g-dependent immunosuppressive state inside the tumor. Concurrent treatment with the immunomodulatory antibodies anti-4-1BB and anti-PD-1 effectively counteracted this tumor immunosuppression, resulting in complete regression of tumors and long-term survival in 70% of the mice.</p> <p><strong>CONCLUSIONS: </strong>The research described in this thesis sheds new light into the mechanisms by which vaccine-mediated CD4<sup>+</sup> T cell responses participate to tumor rejection and autoimmunity. Moreover, our findings indicate that cancer vaccine-induced tumor immunosuppression significantly limits tumor regression, emphasizing the requirement of combinatorial approaches for successful cancer immunotherapy. Overall, our research offers new insight for future vaccine development.</p>","abstract_html":"&lt;p&gt;&lt;strong&gt;INTRODUCTION: &lt;/strong&gt;Pre-clinical and clinical data strongly support the feasibility of employing immunotherapy as a strategy to treat cancer.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;METHODS: &lt;/strong&gt;Using the B16F10 murine melanoma model, we have been investigating mechanisms of T cell-mediated antitumor immunity following immunization with dopachrome tautomerase (DCT), a melanoma-associated antigen.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;RESULTS: &lt;/strong&gt;In &lt;strong&gt;Chapter 2&lt;/strong&gt;, we uncovered an interesting dichotomy whereby DCT-specific CD4&lt;sup&gt;+&lt;/sup&gt; T cell-mediated tumor protection and autoimmunity are dependent on IL-4/STAT-6 and IFN-g/STAT-4, respectively. Our data also revealed that this phenomenon is extrinsic of CD4&lt;sup&gt;+&lt;/sup&gt; T cell polarization.&lt;/p&gt; &lt;p&gt;To gain further insight into the targets recognized by CD4&lt;sup&gt;+&lt;/sup&gt; T cells, we conducted in &lt;strong&gt;Chapter 3&lt;/strong&gt; extensive CD4&lt;sup&gt;+&lt;/sup&gt; T cell epitope mapping experiments using overlapping peptide libraries. Interestingly, while we were able to identify “helper” epitopes within DCT that were required for maximal CD8&lt;sup&gt;+&lt;/sup&gt; T cell expansion, we were unable to identify “effector” epitopes responsible for tumor rejection. Further examination of the requirements for the generation of CD4&lt;sup&gt;+&lt;/sup&gt; T cell effector epitopes showed that post-translational modifications of the protein were involved.&lt;/p&gt; &lt;p&gt;In &lt;strong&gt;Chapter 4&lt;/strong&gt;, we investigated the modest efficacy afforded by DCT immunization in the context of established B16F10 melanomas. Using intratumoral transcriptional analysis, we demonstrated that the vaccine rapidly promoted an IFN-g-dependent immunosuppressive state inside the tumor. Concurrent treatment with the immunomodulatory antibodies anti-4-1BB and anti-PD-1 effectively counteracted this tumor immunosuppression, resulting in complete regression of tumors and long-term survival in 70% of the mice.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;CONCLUSIONS: &lt;/strong&gt;The research described in this thesis sheds new light into the mechanisms by which vaccine-mediated CD4&lt;sup&gt;+&lt;/sup&gt; T cell responses participate to tumor rejection and autoimmunity. Moreover, our findings indicate that cancer vaccine-induced tumor immunosuppression significantly limits tumor regression, emphasizing the requirement of combinatorial approaches for successful cancer immunotherapy. Overall, our research offers new insight for future vaccine development.&lt;/p&gt;","abstract_has_math":false,"creators":["Bernard, Dannie"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Wan, Yonghong","Bramson, Jonathan","Ashkar, Aliahmad"],"committee_chairs":[],"committee_members":[],"year":2011,"date_issued":"2011-10","date_published":"2011-10","updated_at":"2026-11-18T19:39:43Z","subjects":["cancer immunotherapy","T cells","tumor immunity","autoimmunity","immune regulation","viral vectors","Immunity","Immunoprophylaxis and Therapy"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/23814"],"render_values":[{"text":"https://doi.org/10.71548/23814","href":"https://doi.org/10.71548/23814","code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/6146","7169","2234797"],"render_values":[{"text":"opendissertations/6146","href":null,"code":true},{"text":"7169","href":null,"code":true},{"text":"2234797","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/11156","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/11156","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F11156","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Wan, Yonghong","Bramson, Jonathan","Ashkar, Aliahmad"]},{"key":"dc:creator","label":"Author","values":["Bernard, Dannie"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-06-18T16:53:46Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-06-18T16:53:46Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2011-09-13"]},{"key":"dc:date.issued","label":"Date","values":["2011-10"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["cancer immunotherapy","T cells","tumor immunity","autoimmunity","immune regulation","viral vectors","Immunity","Immunoprophylaxis and Therapy"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/6146","7169","2234797"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/11156","https://doi.org/10.71548/23814"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p><strong>INTRODUCTION: </strong>Pre-clinical and clinical data strongly support the feasibility of employing immunotherapy as a strategy to treat cancer.</p> <p><strong>METHODS: </strong>Using the B16F10 murine melanoma model, we have been investigating mechanisms of T cell-mediated antitumor immunity following immunization with dopachrome tautomerase (DCT), a melanoma-associated antigen.</p> <p><strong>RESULTS: </strong>In <strong>Chapter 2</strong>, we uncovered an interesting dichotomy whereby DCT-specific CD4<sup>+</sup> T cell-mediated tumor protection and autoimmunity are dependent on IL-4/STAT-6 and IFN-g/STAT-4, respectively. Our data also revealed that this phenomenon is extrinsic of CD4<sup>+</sup> T cell polarization.</p> <p>To gain further insight into the targets recognized by CD4<sup>+</sup> T cells, we conducted in <strong>Chapter 3</strong> extensive CD4<sup>+</sup> T cell epitope mapping experiments using overlapping peptide libraries. Interestingly, while we were able to identify “helper” epitopes within DCT that were required for maximal CD8<sup>+</sup> T cell expansion, we were unable to identify “effector” epitopes responsible for tumor rejection. Further examination of the requirements for the generation of CD4<sup>+</sup> T cell effector epitopes showed that post-translational modifications of the protein were involved.</p> <p>In <strong>Chapter 4</strong>, we investigated the modest efficacy afforded by DCT immunization in the context of established B16F10 melanomas. Using intratumoral transcriptional analysis, we demonstrated that the vaccine rapidly promoted an IFN-g-dependent immunosuppressive state inside the tumor. Concurrent treatment with the immunomodulatory antibodies anti-4-1BB and anti-PD-1 effectively counteracted this tumor immunosuppression, resulting in complete regression of tumors and long-term survival in 70% of the mice.</p> <p><strong>CONCLUSIONS: </strong>The research described in this thesis sheds new light into the mechanisms by which vaccine-mediated CD4<sup>+</sup> T cell responses participate to tumor rejection and autoimmunity. Moreover, our findings indicate that cancer vaccine-induced tumor immunosuppression significantly limits tumor regression, emphasizing the requirement of combinatorial approaches for successful cancer immunotherapy. Overall, our research offers new insight for future vaccine development.</p>"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (Medical Science)"]},{"key":"dc:title","label":"Title","values":["INVESTIGATING MECHANISMS OF CANCER VACCINE-INDUCED TUMOR IMMUNITY AND AUTOIMMUNITY"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Wan, Yonghong","Bramson, Jonathan","Ashkar, Aliahmad"],"dc:creator":["Bernard, Dannie"],"dc:date.accessioned":["2014-06-18T16:53:46Z"],"dc:date.available":["2014-06-18T16:53:46Z"],"dc:date.created":["2011-09-13"],"dc:date.issued":["2011-10"],"dc:description.abstract":["<p><strong>INTRODUCTION: </strong>Pre-clinical and clinical data strongly support the feasibility of employing immunotherapy as a strategy to treat cancer.</p> <p><strong>METHODS: </strong>Using the B16F10 murine melanoma model, we have been investigating mechanisms of T cell-mediated antitumor immunity following immunization with dopachrome tautomerase (DCT), a melanoma-associated antigen.</p> <p><strong>RESULTS: </strong>In <strong>Chapter 2</strong>, we uncovered an interesting dichotomy whereby DCT-specific CD4<sup>+</sup> T cell-mediated tumor protection and autoimmunity are dependent on IL-4/STAT-6 and IFN-g/STAT-4, respectively. Our data also revealed that this phenomenon is extrinsic of CD4<sup>+</sup> T cell polarization.</p> <p>To gain further insight into the targets recognized by CD4<sup>+</sup> T cells, we conducted in <strong>Chapter 3</strong> extensive CD4<sup>+</sup> T cell epitope mapping experiments using overlapping peptide libraries. Interestingly, while we were able to identify “helper” epitopes within DCT that were required for maximal CD8<sup>+</sup> T cell expansion, we were unable to identify “effector” epitopes responsible for tumor rejection. Further examination of the requirements for the generation of CD4<sup>+</sup> T cell effector epitopes showed that post-translational modifications of the protein were involved.</p> <p>In <strong>Chapter 4</strong>, we investigated the modest efficacy afforded by DCT immunization in the context of established B16F10 melanomas. Using intratumoral transcriptional analysis, we demonstrated that the vaccine rapidly promoted an IFN-g-dependent immunosuppressive state inside the tumor. Concurrent treatment with the immunomodulatory antibodies anti-4-1BB and anti-PD-1 effectively counteracted this tumor immunosuppression, resulting in complete regression of tumors and long-term survival in 70% of the mice.</p> <p><strong>CONCLUSIONS: </strong>The research described in this thesis sheds new light into the mechanisms by which vaccine-mediated CD4<sup>+</sup> T cell responses participate to tumor rejection and autoimmunity. Moreover, our findings indicate that cancer vaccine-induced tumor immunosuppression significantly limits tumor regression, emphasizing the requirement of combinatorial approaches for successful cancer immunotherapy. Overall, our research offers new insight for future vaccine development.</p>"],"dc:description.degree":["Doctor of Philosophy (Medical Science)"],"dc:identifier.other":["opendissertations/6146","7169","2234797"],"dc:identifier.uri":["http://hdl.handle.net/11375/11156","https://doi.org/10.71548/23814"],"dc:subject":["cancer immunotherapy","T cells","tumor immunity","autoimmunity","immune regulation","viral vectors","Immunity","Immunoprophylaxis and Therapy"],"dc:title":["INVESTIGATING MECHANISMS OF CANCER VACCINE-INDUCED TUMOR IMMUNITY AND AUTOIMMUNITY"],"dc:type":["thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:39:43Z"}